SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine
- spícephróitéin réamhleá SARS-CoV-2 chobhsaithe Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
- ga
- SARS-CoV2 prefusion Spike delta TM | stabilised SARS-CoV-2 pre-fusion S protein
- en
- Sainmhíniú pre-fusion spike protein of SARS-CoV-2 as it has been stabilised in order to be used in a vaccine Tagairt COM-Terminology Coordination, based on:- Paul A Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew G Davis, Brandon J Essink, et al. 'Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study' (18.6.2021). Lancet Infect Dis. April 19, 2021- 'Supplementary appendix 2' (18.6.2021). Supplement to: Goepfert PA, Fu B, Chabanon A-L, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet Infect Dis 2021; published online April 19. https://doi.org/10.1016/S1473-3099(21)00147-X